Models for the red blood cell lifespan
- 2 April 2016
- journal article
- research article
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 43 (3) , 259-274
Abstract
The lifespan of red blood cells (RBCs) plays an important role in the study and interpretation of various clinical conditions. Yet, confusion about the meanings of fundamental terms related to cell survival and their quantification still exists in the literature. To address these issues, we started from a compartmental model of RBC populations based on an arbitrary full lifespan distribution, carefully defined the residual lifespan, current age, and excess lifespan of the RBC population, and then derived the distributions of these parameters. For a set of residual survival data from biotin-labeled RBCs, we fit models based on Weibull, gamma, and lognormal distributions, using nonlinear mixed effects modeling and parametric bootstrapping. From the estimated Weibull, gamma, and lognormal parameters we computed the respective population mean full lifespans (95 % confidence interval): 115.60 (109.17–121.66), 116.71 (110.81–122.51), and 116.79 (111.23–122.75) days together with the standard deviations of the full lifespans: 24.77 (20.82–28.81), 24.30 (20.53–28.33), and 24.19 (20.43–27.73). We then estimated the 95th percentiles of the lifespan distributions (a surrogate for the maximum lifespan): 153.95 (150.02–158.36), 159.51 (155.09–164.00), and 160.40 (156.00–165.58) days, the mean current ages (or the mean residual lifespans): 60.45 (58.18–62.85), 60.82 (58.77–63.33), and 57.26 (54.33–60.61) days, and the residual half-lives: 57.97 (54.96–60.90), 58.36 (55.45–61.26), and 58.40 (55.62–61.37) days, for the Weibull, gamma, and lognormal models respectively. Corresponding estimates were obtained for the individual subjects. The three models provide equally excellent goodness-of-fit, reliable estimation, and physiologically plausible values of the directly interpretable RBC survival parameters.Keywords
Funding Information
- National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (K25DK096006)
- Amgen award (20090067)
- The United States Public Health Service NIH Grant (P01 HL046925)
- The Thrasher Research Fund (0285-3)
- The National Center for Research Resources, a part of the NIH (UL1RR024979, UL1TR000039, and 1S10 RR027219)
This publication has 60 references indexed in Scilit:
- Lifespan based indirect response modelsJournal of Pharmacokinetics and Pharmacodynamics, 2012
- Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response modelsJournal of Pharmacokinetics and Pharmacodynamics, 2010
- Red blood cell (RBC) survival determined in humans using RBCs labeled at multiple biotin densitiesTransfusion, 2010
- Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1cBlood, 2008
- Pharmacodynamic modeling of the effect of changes in the environment on cellular lifespan and cellular responseJournal of Pharmacokinetics and Pharmacodynamics, 2008
- Modeling time variant distributions of cellular lifespans: increases in circulating reticulocyte lifespans following double phlebotomies in sheepJournal of Pharmacokinetics and Pharmacodynamics, 2008
- Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cellsJournal of Pharmacokinetics and Pharmacodynamics, 2008
- Pharmacodynamic analysis of time-variant cellular disposition: reticulocyte disposition changes in phlebotomized sheepJournal of Pharmacokinetics and Pharmacodynamics, 2007
- Modelling cell lifespan and proliferation: is likelihood to die or to divide independent of age?Journal of The Royal Society Interface, 2005
- Likelihood Ratio Tests for Model Selection and Non-Nested HypothesesEconometrica, 1989